Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter & Ivo Abraham. (2023) Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert Review of Pharmacoeconomics & Outcomes Research 23:3, pages 297-307.
Read now
Read now
Mok Oh, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Joanne Jeter & Ivo Abraham. (2023) The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Pharmacoeconomics & Outcomes Research 23:3, pages 317-325.
Read now
Read now
Yitian Lang, Bin Wu & Xiaoyan Liu. (2022) Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States. Breast Cancer: Targets and Therapy 14, pages 453-463.
Read now
Read now
Sneha Durgapal, Kent Hanson, Samantha K Kurosky, Sharon Kautz, Steve Sison & Christina Cool. (2022) Work productivity among patients with metastatic breast cancer in the United States. Expert Review of Pharmacoeconomics & Outcomes Research 22:7, pages 1137-1145.
Read now
Read now
Jiangping Yang, Jiaqi Han, Maolang Tian, Kun Tian, Wenjun Liao & Xi Yan. (2020) Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Cancer Management and Research 12, pages 12905-12913.
Read now
Read now
Arielle G. Bensimon, Zheng-Yi Zhou, Madeline Jenkins, Yan Song, Wei Gao, James Signorovitch, Clemens Krepler, Frank Xiaoqing Liu, Jingshu Wang & Raquel Aguiar-Ibáñez. (2019) Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. Journal of Medical Economics 22:10, pages 981-993.
Read now
Read now
Sang Hee Park, Gary Binder, Shelby Corman & Marc Botteman. (2019) Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Journal of Medical Economics 22:8, pages 840-847.
Read now
Read now
Maria Shoaib & Syed Ahsanuddin Ahmed. (2016) Role of natural herbs and phytochemicals to minimize tumor and economic burden in breast cancer treatment. Breast Cancer: Targets and Therapy 8, pages 241-242.
Read now
Read now
Articles from other publishers (17)
Harsimran Sidhu, Lalit Kumar Gautam & Neena Capalash. (2022) Unraveling the molecular mechanism of l-menthol against cervical cancer based on network pharmacology, molecular docking and in vitro analysis. Molecular Diversity 27:1, pages 323-340.
Crossref
Crossref
Zhiyuan Tang, Xin Xu, Jie Gao, Ling Chen, Qiuyan Zhu, Jinli Wang, Xiaoyu Yan, Bohua Chen & Yumei Zhu. (2022) Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China. Frontiers in Public Health 10.
Crossref
Crossref
Jiangping Yang, Jiaqi Han, Yalan Zhang, Muhelisa Muhetaer, Nianyong Chen & Xi Yan. (2022) Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Frontiers in Pharmacology 13.
Crossref
Crossref
Yang Shi, Jigang Chen, Bo Shi & Aihua Liu. (2022) Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer. Gynecologic Oncology 164:2, pages 379-385.
Crossref
Crossref
Byeongsang Oh, Frances Boyle, Nick Pavlakis, Stephen Clarke, Alex Guminski, Thomas Eade, Gillian Lamoury, Susan Carroll, Marita Morgia, Andrew Kneebone, George Hruby, Mark Stevens, Wen Liu, Brian Corless, Mark Molloy, Towia Libermann, David Rosenthal & Michael Back. (2021) Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. Frontiers in Oncology 11.
Crossref
Crossref
Qian Xie, Hanrui Zheng & Qiu Li. (2021) Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. Breast Care, pages 1-6.
Crossref
Crossref
Yingcheng Wang, Mingjun Rui, Xin Guan, Yingdan Cao & Pingyu Chen. (2021) Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective. Frontiers in Medicine 8.
Crossref
Crossref
Rafael Gonzalez, Laura J. Havrilesky, Evan R. Myers, Angeles Alvarez Secord, Joseph A. Dottino, Andrew Berchuck & Haley A. Moss. (2020) Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecologic Oncology 159:2, pages 483-490.
Crossref
Crossref
Jessica N. Semin, David Palm, Lynette M. Smith & Sarah Ruttle. (2020) Understanding breast cancer survivors’ financial burden and distress after financial assistance. Supportive Care in Cancer 28:9, pages 4241-4248.
Crossref
Crossref
Qiuji Wu, Weiting Liao, Mengxi Zhang, Jiaxing Huang, Pengfei Zhang & Qiu Li. (2020) Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives. Frontiers in Oncology 10.
Crossref
Crossref
D. A. Andreev, K. I. Polyakova, A. A. Zavyalov, T. N. Ermolaeva, A. G. Fisun, A. D. Ermolaeva, V. A. Dubovtseva & T. E. Maksimova. (2020) Crucial areas of the economic analysis of public cancer care. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 12:4, pages 310-317.
Crossref
Crossref
Marc Botteman, Katharina Nickel, Shelby Corman, Marco Turini & Gary Binder. (2019) Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Supportive Care in Cancer 28:2, pages 857-866.
Crossref
Crossref
Lorraine T. Dean, Shadiya L. Moss, Yusuf Ransome, Livia Frasso-Jaramillo, Yuehan Zhang, Kala Visvanathan, Lauren Hersch Nicholas & Kathryn H. Schmitz. (2018) “It still affects our economic situation”: long-term economic burden of breast cancer and lymphedema. Supportive Care in Cancer 27:5, pages 1697-1708.
Crossref
Crossref
Joseph A. Dottino, Haley A. Moss, Karen H. Lu, Angeles A. Secord & Laura J. Havrilesky. (2019) U.S. Food and Drug Administration–Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer. Obstetrics & Gynecology 133:4, pages 795-802.
Crossref
Crossref
Holly Guy, Lydia Walder & Mark Fisher. (2018) Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. PharmacoEconomics 37:3, pages 391-405.
Crossref
Crossref
Lorraine T. Dean, Kathryn H. Schmitz, Kevin D. Frick, Lauren H. Nicholas, Yuehan Zhang, S. V. Subramanian & Kala Visvanathan. (2018) Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA. Journal of Cancer Survivorship 12:3, pages 306-315.
Crossref
Crossref
Karin Berger, Dorothee Schopohl, Antonia Bollig, Dorothea Strobach, Christina Rieger, Dale Rublee & Helmut Ostermann. (2018) Burden of Oral Mucositis: A Systematic Review and Implications for Future Research. Oncology Research and Treatment 41:6, pages 399-405.
Crossref
Crossref